AVALYN PHARMA INC (US.AVLN)
Capital Allocation Audit · Period: 2024 – 2026
Key Metrics
US.AVLN · YoY: 2026 Q1 vs 2025 Q1
| Metric | Value | YoY |
|---|---|---|
| FCF Conversion | 101.1% | → |
| ROE | - | → |
| Cash Conversion | - | → |
| D/E Ratio | - | → |
| Gross Margin | - | → |
US.AVLN (AVALYN PHARMA INC) | YoY: 2026 Q1 vs 2025 Q1 Metric Value YoY ---------------------------- FCF Conversion 101.1% → ROE - → Cash Conversion - → D/E Ratio - → Gross Margin - →
Key Metrics
US.AVLN (AVALYN PHARMA INC) | YoY: 2026 Q1 vs 2025 Q1
Metric Value YoY----------------------------FCF Conversion 101.1% →ROE - →Cash Conversion - →D/E Ratio - →Gross Margin - →Audit Dimensions
Unlimited Companies
AppleMicrosoftAlphabet-CAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesMicron TechnologySanDiskSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies